Back to search

Netherlands· NL-118ec1bd20a2

Velsipity 2 mg filmomhulde tablet

A etrasimod product containing etrasimod arginine, registered in Netherlands by Pfizer Europe MA EEIG. The same ATC class is registered in 13 of our 19 countries.

ATC L04AE05

Checked against CBG-MEB (Netherlands) on

Informational only — not a medical device.

SOURCE REGISTER · NLCBG-MEB (Netherlands)normalisedVelsipity 2 mg filmomhulde tabletATCL04AE05REGISTER NO.NL-118ec1bd20a2PACKS LISTED1CHECKEDSeptember 29, 2026

Where it is registered

Etrasimod is registered in 13 of 19 countries.

Countries holding a registration under ATC L04AE05 (etrasimod), each read from that country’s own register.

  • This record: Netherlands, from CBG-MEB (Netherlands)
  • 8 of them publish a price we can compare per daily dose

Etrasimod · ATC L04AE05

13 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Ireland
  • Netherlands
  • Norwayprice
  • Polandprice
  • Spainprice
  • Switzerlandprice
  • United Kingdom
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of etrasimod costs, country by country.

Normalised to the WHO defined daily dose (2 mg), so markets compare like for like.

  • 1 market with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown

Etrasimod · price per daily dose (2 mg)

USD · FX 28 Sept 2026

  • CH Switzerland$35.97
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

CBG-MEB (Netherlands)
Active substance
ETRASIMOD ARGININE
Manufacturer
Pfizer Europe MA EEIG
Country
Netherlands (NL)
ATC code
L04AE05
ATC class
Etrasimod
Defined daily dose
2 mg, O
Reimbursed
Not published by this register
Source register
CBG-MEB (Netherlands)
Last checked
September 29, 2026

Packs & prices · 1

  • cbg_meb_id
    EU/1/23/1790

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/a8d5c3f1-ef1a-4ae9-845f-cc4a9ed9872d
GET /v1/drugs/a8d5c3f1-ef1a-4ae9-845f-cc4a9ed9872d?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Filmomhulde tablet",
  "route": "Oraal gebruik",
  "soort": null,
  "source": "cbg_meb",
  "smpc_url": "https://www.ema.europa.eu/en/documents/product-information/velsipity-epar-product-information_nl.pdf",
  "strength": null,
  "atc_label": "Etrasimod",
  "detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/cp130781",
  "excipients": [
    "BRILJANTBLAUW FCF ALUMINIUMLAK (E133)",
    "CELLULOSE, MICROKRISTALLIJN (E 460(i))",
    "INDIGOKARMIJN ALUMINIUMLAK (E 132)",
    "MACROGOL 3350",
    "MAGNESIUMSTEARAAT (E 470b)",
    "MANNITOL (D-) (E 421)",
    "NATRIUMZETMEELGLYCOLAAT",
    "POLYVINYLALCOHOL (E 1203)",
    "TALK (E 553b)",
    "TARTRAZINE ALUMINIUMLAK (E 102)",
    "TITAANDIOXIDE (E 171)"
  ],
  "substances": [
    "ETRASIMOD ARGININE"
  ],
  "leaflet_url": null,
  "authorised_at": "2024/02/16",
  "procedure_number": "EMEA/H/C/006007",
  "dispensing_status": "Uitsluitend recept",
  "registration_number": "EU/1/23/1790",
  "additional_monitoring": "Y"
}

See everything about etrasimod.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.